New clinical trials in Japan: 981 since Nov 2024

Name: New clinical trials in Japan
Creator: SpecStream
License: https://creativecommons.org/licenses/by/4.0/

The full list. New clinical trials with a site in Japan: 981 rows for $49.05, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. The list gains about 25 rows a month. The new rows come each week by email, $19 a month.

Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The weekly rows run until you cancel, from the link in each delivery. The rows on this page are a sample.

For agents and scripts: this list is ordered at https://specstream.ai/data/clinical-trials/country/japan, and every list with its row count and price is at https://specstream.ai/data/lists.json.

Updated November 9, 2026. Source: ClinicalTrials.gov API v2 (U.S. National Library of Medicine).

981 clinical studies with a site in Japan were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 863 have an industry sponsor and 750 are recruiting or about to. The newest, NCT07926334, was posted on November 9, 2026: A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer... (Boehringer Ingelheim).

The request: Every new clinical trial with a site in Japan, with the sponsor, phase, conditions and the listed contact. $10 of credit on sign-up, no card.

Get new trials like these Watch a sponsor

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

981New trials
863Industry sponsored
750Recruiting or not yet
November 9, 2026Latest posted

Newest trials

The newest 100 of 981, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

First posted	NCT ID	Title	Sponsor	Phase	Status	Conditions	Enrollment	Countries	Source
November 9, 2026	NCT07926334	A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation	Boehringer Ingelheim	Phase 1	Not yet recruiting	Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	200	Australia, Japan, South Korea, Spain, United States	clinicaltrials.gov
November 9, 2026	NCT07926321	A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment	Boehringer Ingelheim	Phase 2	Not yet recruiting	Idiopathic Pulmonary Fibrosis	70	Belgium, Finland, Germany, Japan, Mexico, South Korea, Spain, United States	clinicaltrials.gov
November 9, 2026	NCT07926308	Real-world Outcome of Zongertinib in Japan (J-HERZ)	Boehringer Ingelheim	Observational	Not yet recruiting	Non-small Cell Lung Cancer	300	Japan	clinicaltrials.gov
November 5, 2026	NCT07919405	A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and...	Novo Nordisk A/S	Phase 3	Not yet recruiting	Hypertension, Obesity	1,408	Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Denmark, Germany...	clinicaltrials.gov
November 4, 2026	NCT07917728	Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICU	Columbia University	Observational	Recruiting	Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Cardiac Arrest (CA)	240	Brazil, Canada, Colombia, Japan, United States	clinicaltrials.gov
November 4, 2026	NCT07915219	A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)	Boehringer Ingelheim	Phase 3	Not yet recruiting	Bronchiectasis	1,500	Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia...	clinicaltrials.gov
November 3, 2026	NCT07913568	A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell...	National Cancer Center, Japan	Phase 2	Not yet recruiting	Ovarian Clear Cell Carcinoma	32	Japan	clinicaltrials.gov
November 3, 2026	NCT07913347	Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study)	Metagen Therapeutics, Inc.	Phase 1/2	Recruiting	Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate	54	Japan, United States	clinicaltrials.gov
October 30, 2026	NCT07906106	A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)	Juro Sciences Inc.	Phase 2	Recruiting	Participants With Underactive Bladder (UAB)	70	Japan	clinicaltrials.gov
October 28, 2026	NCT07900633	A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk	Eli Lilly and Company	Phase 3	Not yet recruiting	Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2	3,000	Argentina, Australia, Brazil, Canada, China, Czechia, France, Germany, Hungary...	clinicaltrials.gov
October 20, 2026	NCT07884318	Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease	Metcela Inc.	Observational	Recruiting	Single Ventricle, Hypoplastic Left Heart Syndrome (HLHS)	40	Japan	clinicaltrials.gov
October 19, 2026	NCT07881458	A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes	Eli Lilly and Company	Phase 3	Recruiting	Obesity, Overweight, Diabetes Mellitus, Type 2	1,000	Brazil, China, Germany, Japan, Puerto Rico, Romania, South Korea, Spain...	clinicaltrials.gov
October 19, 2026	NCT07881432	A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes	Eli Lilly and Company	Phase 3	Not yet recruiting	Obesity	2,115	Argentina, China, Germany, India, Japan, Puerto Rico, South Korea, United...	clinicaltrials.gov
October 14, 2026	NCT07872722	Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction...	National Cancer Center, Japan	Phase 2	Recruiting	CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma	29	Japan	clinicaltrials.gov
October 13, 2026	NCT07872449	Risankizumab for Refractory Perianal Fistulizing Crohn's Disease	Yuki Horio	Phase 4	Recruiting	Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease	25	Japan	clinicaltrials.gov
October 13, 2026	NCT07871214	A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage...	Bristol-Myers Squibb	Phase 2	Not yet recruiting	Early-Stage Non-Small Cell Lung Cancer	80	Australia, Canada, China, France, Germany, Italy, Japan, Poland, Romania, South...	clinicaltrials.gov
October 13, 2026	NCT07870837	Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan	iRhythm Technologies, Inc.	Not applicable	Not yet recruiting	Atrial Fibrillation (AF), Atrial Flutter, Supraventricular Tachycardia (SVT), Ventricular Tachycardia (VT), Ventricular...	130	Japan	clinicaltrials.gov
October 9, 2026	NCT07867080	A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).	4D Molecular Therapeutics	Phase 3	Recruiting	Diabetic Macular Edema (DME)	514	China, Japan, Puerto Rico, United States	clinicaltrials.gov
October 7, 2026	NCT07862088	Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula	Tokyo University	Observational	Recruiting	Acute Pancreatitis, Pancreatic Fluid Collection, Postoperative Pancreatic Fistula	5,000	Japan	clinicaltrials.gov
October 6, 2026	NCT07861100	A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular...	Novo Nordisk A/S	Phase 3	Not yet recruiting	Cardiovascular Risk, Obesity	8,500	Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, Denmark...	clinicaltrials.gov
October 2, 2026	NCT07855692	The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)	Nagoya University	Phase 2	Recruiting	HFpEF - Heart Failure With Preserved Ejection Fraction	90	Japan	clinicaltrials.gov
October 1, 2026	NCT07851103	A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer	Boehringer Ingelheim	Phase 1	Recruiting	Advanced Solid Tumour	90	Belgium, France, Japan, Spain, United States	clinicaltrials.gov
October 1, 2026	NCT07851025	Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced...	AstraZeneca	Phase 3	Recruiting	Epithelial Ovarian Cancer	950	Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Colombia...	clinicaltrials.gov
September 28, 2026	NCT07843940	A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)	Boehringer Ingelheim	Phase 1/2	Recruiting	Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer	55	Australia, Belgium, China, France, Germany, Japan, Netherlands, Poland, Spain...	clinicaltrials.gov
September 28, 2026	NCT07843459	A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)	Eli Lilly and Company	Phase 1	Not yet recruiting	Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma	111	China, Japan, United States	clinicaltrials.gov
September 24, 2026	NCT07839871	Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease	Pfizer	Phase 3	Recruiting	Respiratory Syncytial Virus (RSV)	920	Japan, Poland, Spain, United States	clinicaltrials.gov
September 24, 2026	NCT07838220	A Study of IBI3016 in Japanese Participants	Innovent Biologics (Suzhou) Co. Ltd.	Phase 1	Recruiting	Hypertension	30	Japan	clinicaltrials.gov
September 22, 2026	NCT07832747	A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT	Ono Pharmaceutical Co., Ltd.	Phase 2	Not yet recruiting	Tenosynovial Giant Cell Tumor	18	Japan	clinicaltrials.gov
September 21, 2026	NCT07832292	A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer	Janssen Research & Development, LLC	Phase 2	Recruiting	Prostatic Neoplasms	100	Australia, China, Japan, United States	clinicaltrials.gov
September 21, 2026	NCT07830732	A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia A	Novo Nordisk A/S	Phase 3	Recruiting	Haemophilia A	84	Argentina, Australia, Brazil, Canada, Denmark, France, Germany, Greece, India...	clinicaltrials.gov
September 21, 2026	NCT07830719	Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP	Novartis Pharmaceuticals	Phase 2	Recruiting	Coronary Artery Disease	180	Australia, Germany, Japan, United Kingdom, United States	clinicaltrials.gov
September 18, 2026	NCT07827144	A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)	AIMEDBIO	Phase 1	Recruiting	Solid Tumours	86	Australia, France, Japan, South Korea, United States	clinicaltrials.gov
September 16, 2026	NCT07822061	AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight	Novo Nordisk A/S	Phase 3	Recruiting	Overweight, Obesity	400	Japan	clinicaltrials.gov
September 15, 2026	NCT07819526	Acute Ischemic Stroke in Patients With Active Cancer	Osaka University	Observational	Recruiting	Acute Ischemic Stroke, Active Cancer	500	Japan	clinicaltrials.gov
September 14, 2026	NCT07816666	Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer	AstraZeneca	Phase 3	Recruiting	Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer...	600	Australia, Brazil, Canada, China, Germany, India, Italy, Japan, South Korea...	clinicaltrials.gov
September 11, 2026	NCT07816328	Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately...	Novartis Pharmaceuticals	Phase 3	Recruiting	Chronic Spontaneous Urticaria	382	Canada, Hong Kong, Japan, South Korea	clinicaltrials.gov
September 8, 2026	NCT07806266	EORTC Metastatic Breast Cancer Module Development	University of Leeds	Observational	Recruiting	Metastatic Beast Cancer	568	Belgium, Canada, France, Germany, India, Italy, Japan, Jordan, Netherlands...	clinicaltrials.gov
September 3, 2026	NCT07802704	A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]	GlaxoSmithKline	Phase 3	Recruiting	Neoplasms, Prostate	684	Australia, Canada, Japan, South Korea	clinicaltrials.gov
September 3, 2026	NCT07801508	A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors	Novartis Pharmaceuticals	Phase 1	Recruiting	Advanced Gastroesophageal Adenocarcinoma, Advanced Breast Cancer, Triple-negative Breast Cancer, Advanced Non-small...	66	Australia, Japan	clinicaltrials.gov
September 3, 2026	NCT07801339	Clinical Evaluation of Immediate Dental Implants in Very Elderly Patients.	Takane Dental Clinic	Observational	Enrolling by invitation	Tooth Loss / Rehabilitation	15	Japan	clinicaltrials.gov
August 31, 2026	NCT07794774	A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)	Pfizer	Phase 3	Recruiting	Obesity	197	Japan	clinicaltrials.gov
August 31, 2026	NCT07794761	A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)	Pfizer	Phase 3	Recruiting	Obesity	180	Japan	clinicaltrials.gov
August 31, 2026	NCT07794579	A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1...	Eli Lilly and Company	Phase 3	Recruiting	Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal	2,001	Argentina, China, Czechia, Germany, India, Japan, Mexico, Puerto Rico, South...	clinicaltrials.gov
August 28, 2026	NCT07793513	Study of BK1803 in Healthy Infants	Tanabe Pharma Corporation	Phase 3	Not yet recruiting	Pertussis, Diphtheria, Tetanus, Poliomyelitis, Hepatitis B, Haemophilus Influenzae Type b	344	Japan	clinicaltrials.gov
August 28, 2026	NCT07789483	An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy	Alexion Pharmaceuticals, Inc.	Phase 3	Not yet recruiting	Transthyretin Amyloid Cardiomyopathy (ATTR-CM)	1,180	Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia...	clinicaltrials.gov
August 27, 2026	NCT07789015	A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies	Boehringer Ingelheim	Phase 3	Not yet recruiting	Idiopathic Inflammatory Myopathies	270	Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Czechia...	clinicaltrials.gov
August 26, 2026	NCT07787208	A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors	Ono Pharmaceutical Co., Ltd.	Phase 1	Recruiting	Solid Tumors	80	Japan	clinicaltrials.gov
August 26, 2026	NCT07787182	A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease	Eli Lilly and Company	Phase 1	Recruiting	Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid	68	China, Japan, United States	clinicaltrials.gov
August 26, 2026	NCT07787169	A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease	Eli Lilly and Company	Phase 1	Recruiting	Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers	179	China, Japan, United States	clinicaltrials.gov
August 25, 2026	NCT07784725	A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2...	AstraZeneca	Phase 3	Recruiting	Obesity or Overweight	2,500	Argentina, Australia, Brazil, Bulgaria, Canada, China, Czechia, France...	clinicaltrials.gov
August 25, 2026	NCT07784270	A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight	AstraZeneca	Phase 3	Recruiting	Obesity or Overweight, Diabetes Mellitus, Type 2	1,500	Argentina, Australia, Canada, Chile, China, Germany, Hungary, India, Japan...	clinicaltrials.gov
August 25, 2026	NCT07783802	A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event	Eli Lilly and Company	Phase 2	Recruiting	Atherosclerosis, Cardiovascular Disease, Obesity, Hypertension, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic	120	Argentina, Japan, Puerto Rico, United States	clinicaltrials.gov
August 24, 2026	NCT07783425	A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema	Pfizer	Phase 3	Recruiting	Atopic Dermatitis	1,375	Canada, Japan, Taiwan, United States	clinicaltrials.gov
August 24, 2026	NCT07782970	A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps...	GlaxoSmithKline	Phase 3	Recruiting	Nasal Polyps	218	Japan, Puerto Rico, United States	clinicaltrials.gov
August 21, 2026	NCT07780669	A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very...	GlaxoSmithKline	Phase 3	Recruiting	Pulmonary Disease, Chronic Obstructive	624	Japan, United States	clinicaltrials.gov
August 21, 2026	NCT07778316	Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)	Amgen	Phase 3	Recruiting	Small Cell Lung Cancer	400	Australia, China, Japan, Switzerland, United States	clinicaltrials.gov
August 20, 2026	NCT07776509	A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With...	AstraZeneca	Phase 3	Recruiting	Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2	500	Argentina, Brazil, Canada, China, Denmark, Israel, Japan, Sweden, Turkey...	clinicaltrials.gov
August 20, 2026	NCT07775300	A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder	Eli Lilly and Company	Phase 3	Recruiting	Depressive Disorder, Major	1,000	Australia, Brazil, Canada, China, Germany, Greece, Japan, Mexico, Poland...	clinicaltrials.gov
August 19, 2026	NCT07774975	Safety Evaluation Study of Pitavastatin PLGA Nano-particle for Retinitis Pigmentosa	Kyushu University	Phase 1	Recruiting	Retinitis Pigmentosa (RP)	21	Japan	clinicaltrials.gov
August 19, 2026	NCT07773727	A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN	argenx	Phase 2	Recruiting	Immunoglobulin A Nephropathy (IgAN)	120	Japan, United States	clinicaltrials.gov
August 19, 2026	NCT07772921	A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma	Pfizer	Phase 3	Recruiting	Asthma	1,100	Japan, United States	clinicaltrials.gov
August 19, 2026	NCT07772492	A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata	AbbVie	Phase 3	Recruiting	Severe Alopecia Areata	300	Australia, Japan, Taiwan, United States	clinicaltrials.gov
August 18, 2026	NCT07769502	A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults...	AbbVie	Phase 2	Recruiting	Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma	168	Israel, Japan, Taiwan, United States	clinicaltrials.gov
August 17, 2026	NCT07769086	Breakthrough Platform Trial for PCAS	Kagawa University	Not applicable	Not yet recruiting	Cardiac Arrest (CA), Post Cardiac Arrest Syndrome	630	Japan	clinicaltrials.gov
August 17, 2026	NCT07767890	A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients	Novartis Pharmaceuticals	Observational	Recruiting	Spinal Muscular Atrophy	80	Japan	clinicaltrials.gov
August 14, 2026	NCT07766018	A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer	Stemline Therapeutics, Inc.	Phase 2	Recruiting	Breast Cancer	70	Japan	clinicaltrials.gov
August 14, 2026	NCT07765888	A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema	Pfizer	Phase 3	Recruiting	Atopic Dermatitis	375	Japan, United States	clinicaltrials.gov
August 14, 2026	NCT07765511	A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes	Eli Lilly and Company	Phase 1	Not yet recruiting	Obesity, Overweight	60	Japan	clinicaltrials.gov
August 14, 2026	NCT07764978	Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT	AstraZeneca	Phase 3	Recruiting	Newly Diagnosed Multiple Myeloma	750	Australia, Brazil, Canada, Denmark, France, Germany, Italy, Japan, Poland...	clinicaltrials.gov
August 13, 2026	NCT07763457	Japanese Strabismus Outcomes Assessment and Research Group Study	Kyoto University, Graduate School of Medicine	Observational	Not yet recruiting	Strabismus	10,000	Japan	clinicaltrials.gov
August 12, 2026	NCT07761117	A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF	AstraZeneca	Phase 3	Recruiting	Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)	6,950	Argentina, Australia, Austria, Brazil, Bulgaria, Canada, China, Czechia...	clinicaltrials.gov
August 12, 2026	NCT07759245	A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)	Eli Lilly and Company	Phase 2	Recruiting	Pulmonary Disease, Chronic Obstructive	606	Argentina, Austria, Canada, China, Czechia, Denmark, France, Germany, Hungary...	clinicaltrials.gov
August 10, 2026	NCT07755826	Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan	Bristol-Myers Squibb	Observational	Recruiting	NTRK Fusion-positive Solid Tumors	20	Japan	clinicaltrials.gov
August 10, 2026	NCT07753993	A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.	AstraZeneca	Phase 3	Recruiting	Chronic Kidney Disease	7,000	Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark...	clinicaltrials.gov
August 7, 2026	NCT07753005	HISTOACRYL® Used for Embolization of Thoracoabdominal Artery Bleeding	Aesculap AG	Observational	Not yet recruiting	Hemorrhage, Gastrointestinal Hemorrhage, Hemoptysis, Postpartum Hemorrhage	176	Japan	clinicaltrials.gov
August 6, 2026	NCT07750353	A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas	National Cancer Center, Japan	Phase 2	Not yet recruiting	Unresectable Thymic Carcinoma	35	Japan	clinicaltrials.gov
August 6, 2026	NCT07748624	A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE)...	Novartis Pharmaceuticals	Phase 2	Recruiting	VEXAS Syndrome	120	Japan	clinicaltrials.gov
August 5, 2026	NCT07746687	A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma	Janssen Research & Development, LLC	Phase 2	Recruiting	Asthma	440	Argentina, China, Israel, Japan, United States	clinicaltrials.gov
August 5, 2026	NCT07746544	Study of Secutrelvir in Participants With COVID-19	Shionogi	Phase 3	Recruiting	COVID-19	1,200	Japan	clinicaltrials.gov
August 4, 2026	NCT07744126	A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV...	AbbVie	Phase 2	Recruiting	Head and Neck Squamous Cell Carcinoma	150	Japan, Taiwan, United States	clinicaltrials.gov
August 4, 2026	NCT07743996	Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis...	Boehringer Ingelheim	Observational	Completed	Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis	122	Japan	clinicaltrials.gov
August 4, 2026	NCT07743580	A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease	Shionogi	Phase 3	Recruiting	SARS-CoV-2	2,000	Bulgaria, Japan, United States	clinicaltrials.gov
August 3, 2026	NCT07742735	A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome...	VectivBio AG	Phase 3	Recruiting	Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF)	124	Argentina, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark...	clinicaltrials.gov
July 31, 2026	NCT07739966	A Study of DS-3939a in Participants With Solid Tumors	Daiichi Sankyo	Phase 1/2	Recruiting	Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer	400	Argentina, Austria, Belgium, Brazil, China, France, Italy, Japan, Spain...	clinicaltrials.gov
July 31, 2026	NCT07739446	Effect of Surgical Masks in Preventing Acute Respiratory Infections	Chiba University	Not applicable	Enrolling by invitation	Acute Respiratory Infections (ARIs), Influenza, COVID - 19	2,400	Japan	clinicaltrials.gov
July 31, 2026	NCT07738952	Safety and Efficacy Study of Sivelestat in Neuromyelitis Optica Spectrum Disorder	Kyushu University	Phase 1/2	Recruiting	Neuromyelitis Optica Spectrum Disorder Attack	7	Japan	clinicaltrials.gov
July 30, 2026	NCT07735637	A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed...	AstraZeneca	Phase 3	Recruiting	Newly Diagnosed Multiple Myeloma (NDMM)	750	Australia, Brazil, Canada, China, Denmark, France, Germany, Italy, Japan...	clinicaltrials.gov
July 29, 2026	NCT07734116	A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.	Ono Pharmaceutical Co., Ltd.	Phase 1/2	Recruiting	Pediatric Malignant Solid Tumor and Epithelioid Sarcoma	50	Japan	clinicaltrials.gov
July 29, 2026	NCT07733765	A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as...	Pfizer	Phase 3	Recruiting	Alopecia Areata	336	Canada, China, Japan, South Korea, United States	clinicaltrials.gov
July 29, 2026	NCT07733180	A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC	BeOne Medicines	Phase 2	Recruiting	Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma	30	Japan	clinicaltrials.gov
July 28, 2026	NCT07732361	A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic...	Alexion Pharmaceuticals, Inc.	Observational	Completed	Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplant	307	Belgium, Brazil, France, Greece, Italy, Japan, South Korea, Spain, United...	clinicaltrials.gov
July 28, 2026	NCT07730021	A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors	Astellas Pharma Global Development, Inc.	Phase 1/2	Recruiting	Locally Advanced or Metastatic Solid Tumors	392	Japan, United States	clinicaltrials.gov
July 27, 2026	NCT07729657	Verification Study of the Effects of Consumption of the Test Food on the Musculoskeletal System	Bloomage Biotechnology Corp., Ltd.	Not applicable	Not yet recruiting	Healthy Japanese Individuals	90	Japan	clinicaltrials.gov
July 24, 2026	NCT07726147	Phase 1, First in Human (FIH), Open-Label, Single-Arm, Ascending Dose Study to Assess the Safety, Tolerability and Preliminary...	Immunomic Therapeutics, Inc.	Phase 1	Recruiting	Allergen Immunotherapy	45	Japan	clinicaltrials.gov
July 23, 2026	NCT07722962	Additional Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury	Kringle Pharma, Inc.	Phase 3	Not yet recruiting	Acute Spinal Cord Injury (SCI)	10	Japan	clinicaltrials.gov
July 23, 2026	NCT07722507	Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis	Bristol-Myers Squibb	Observational	Not yet recruiting	Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis	40	Japan	clinicaltrials.gov
July 22, 2026	NCT07720284	An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC	AstraZeneca	Phase 3	Recruiting	High-risk Muscle Invasive Urothelial Carcinoma	915	Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Poland...	clinicaltrials.gov
July 22, 2026	NCT07720258	Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based...	National Cancer Center, Japan	Phase 2	Not yet recruiting	Advanced Small Bowel Adenocarcinoma	27	Japan	clinicaltrials.gov
July 21, 2026	NCT07717411	A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease	Hoffmann-La Roche	Phase 3	Recruiting	Alzheimer's Disease	1,600	Argentina, Australia, Brazil, Canada, Chile, China, Japan, Taiwan, United...	clinicaltrials.gov
July 21, 2026	NCT07716098	A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression	Janssen Research & Development, LLC	Phase 3	Recruiting	Depressive Disorder, Treatment-Resistant	348	China, Japan, Taiwan, United States	clinicaltrials.gov

Sponsors posting most

Sponsor	New trials	Latest
AstraZeneca	69	October 1, 2026
Eli Lilly and Company	68	October 28, 2026
Pfizer	52	September 24, 2026
Novartis Pharmaceuticals	46	September 21, 2026
Bristol-Myers Squibb	40	October 13, 2026
GlaxoSmithKline	39	September 3, 2026
AbbVie	38	August 19, 2026
Merck Sharp & Dohme LLC	35	June 15, 2026
Boehringer Ingelheim	34	November 9, 2026
Sanofi	26	April 29, 2026
Janssen Research & Development, LLC	24	September 21, 2026
Takeda	23	June 15, 2026
Amgen	22	August 21, 2026
Novo Nordisk A/S	18	November 5, 2026
Ono Pharmaceutical Co., Ltd.	18	September 22, 2026
Hoffmann-La Roche	16	July 21, 2026
Daiichi Sankyo	13	July 31, 2026
Bayer	11	May 5, 2026
Taisho Pharmaceutical Co., Ltd.	11	April 23, 2026
argenx	10	August 19, 2026

Conditions

Condition group	New trials	Latest
Carcinoma, Non-Small-Cell Lung	55	November 9, 2026
Obesity	47	November 5, 2026
Neoplasms	35	September 15, 2026
Overweight	34	October 28, 2026
Breast Neoplasms	30	September 3, 2026
Diabetes Mellitus, Type 2	27	October 28, 2026
Prostatic Neoplasms	24	September 21, 2026
Colorectal Neoplasms	24	June 5, 2026
Colitis, Ulcerative	21	November 3, 2026
Small Cell Lung Carcinoma	20	September 28, 2026
Stomach Neoplasms	19	October 14, 2026
Alzheimer Disease	19	September 28, 2026
Ovarian Neoplasms	19	September 14, 2026
Lung Neoplasms	19	May 22, 2026
Neoplasm Metastasis	17	October 13, 2026
Multiple Myeloma	17	August 14, 2026
Dermatitis, Atopic	16	August 24, 2026
Hypertension	15	November 5, 2026
Endometrial Neoplasms	15	July 6, 2026
Recurrence	14	May 27, 2026
Renal Insufficiency, Chronic	12	August 25, 2026
Pulmonary Disease, Chronic Obstructive	12	August 21, 2026
Lupus Erythematosus, Systemic	12	June 5, 2026
Cardiovascular Diseases	11	October 28, 2026
Heart Failure	11	August 12, 2026

By phase

Phase	New trials	Latest
Phase 3	411	November 5, 2026
Phase 2	187	November 9, 2026
Phase 1	101	November 9, 2026
Observational	96	November 9, 2026
Phase 1/2	70	November 3, 2026
Not applicable	61	October 13, 2026
Phase 2/3	31	June 15, 2026
Phase 4	23	October 13, 2026
Early phase 1	1	March 21, 2025

Where the register publishes

U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.